- Anixa Biosciences Inc ANIX has announced that a genomic variant analysis indicates that its potential compounds may be more effective against the Delta variant than the original wild-type SARS-CoV-2.
- Anixa's program, in collaboration with European partner MolGenie, focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the virus.
- The current compounds that Anixa is synthesizing and evaluating have demonstrated their ability to inhibit the function of this protein, which the virus needs to replicate.
- Sequence analysis of several Delta variant samples demonstrates that the Mpro enzyme often has a mutation that replaces an asparagine (an amino acid) with leucine (another amino acid) near the binding site.
- This change makes the binding pocket of Mpro more hydrophobic, thus suggesting Anixa's compounds will be more potent inhibitors of the variant Mpro than the wild-type (original).
- Price Action: ANIX shares are up 9.45% at $4.98 during the market session on the last check Wednesday.
- Photo by Arek Socha from Pixabay
Loading...
Loading...
ANIXAnixa Biosciences Inc
$3.303.45%
Edge Rankings
Momentum
88.73
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.